Related Experiment Video

Updated: Jun 11, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A

Lenci K Vázquez-Jiménez1,2, Gildardo Rivera1, Alfredo Juárez-Saldivar1

  • 1Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.

Pharmaceutics
|September 28, 2024
PubMed

Insights

Researchers reviewed Janus kinase 2/3 (JAK2/3) inhibitors for cancer treatment. Computer-aided studies and natural compounds show promise, but further research is essential for human clinical approval.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Cancer is a leading global cause of mortality.
  • Janus kinases 2/3 (JAK2/3) are critical in immunity and hematopoiesis, making them key drug targets for cancer therapy.
  • Developing selective JAK inhibitors is a current research focus.

Purpose of the Study:

  • To review current computer-aided strategies and biological evaluations for JAK2/3 inhibitors.
  • To explore novel inhibitors for JAK2/3 targeting in cancer treatment.

Main Methods:

  • Review of computer-aided drug design studies.
  • Analysis of biological evaluations of JAK2/3 inhibitors.
  • Investigation of natural product-derived inhibitors.

Main Results:

  • Synthesized JAK2/3 inhibitors frequently incorporate heterocyclic aromatic rings (e.g., pyrimidine, pyridine).
  • Natural inhibitors from plant extracts and insects exhibit significant inhibitory potential.
  • Computer-aided studies identified key features for JAK2/3 binding.
  • Inhibition of JAK receptors impacts associated signaling pathways.

Conclusions:

  • Reviewed compounds demonstrate promising in vitro and in vivo inhibitory activity against JAK2/3.
  • Further comprehensive studies are required to translate these findings into human cancer treatments.
Keywords:
JAK2JAK3anticancercompounds

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K